✦ LIBER ✦

A novel treatment strategy targeting shugoshin 1 in hematological malignancies

✍ Scribed by Jing Yang; Takayuki Ikezoe; Chie Nishioka; Akihito Yokoyama

Book ID: 119318229
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 804 KB
Volume: 37
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2012.10.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A novel treatment strategy targeting pol

A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies

✍ Nishioka, C; Takezaki, Y; Tasaka, T; Togitani, K; Koeffler, H P; Yokoyama, A; Ik 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 966 KB

Epigenetic manipulation of the immune re

Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies

✍ Craddock, Charles 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 72 KB

Targeting the liver kinase B1/AMP-activa

Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies

✍ Martelli, Alberto M; Chiarini, Francesca; Evangelisti, Camilla; Ognibene, Andrea 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 390 KB

Focal adhesion kinase as a target in the

Focal adhesion kinase as a target in the treatment of hematological malignancies

✍ Bu Yin 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Bortezomib, a novel proteasome inhibitor

Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies

✍ Graham Jackson; Hermann Einsele; Phillippe Moreau; Jesus San Miguel 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 239 KB

Targeting cytotoxic T-lymphocyte antigen

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) : A novel strategy for the treatment of melanoma and other malignancies

✍ Steven J. O'Day; Omid Hamid; Walter J. Urba 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 511 KB

## Abstract Cancer immunotherapy centers on modulating the host's tumor‐directed immune response. One promising approach involves augmentation of cell‐mediated immunity by interrupting T‐cell pathways responsible for immune down‐regulation or tolerance. The discovery of cytotoxic T‐lymphocyte antig